Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHB810 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07529808Phase 2Recruiting
- Sponsor
- BigHat Biosciences
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Antibody-Drug Conjugates (ADCs), Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of BHB810 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by BigHat Biosciences. Started Jul 2026; status: recruiting.
02
Drugs
BHB810
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07529808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529808.